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Why was the cohort set up?
Latin America and the Caribbean (LAC) are characterized
by much diversity in terms of socio-economic status, ecol-
ogy, environment, access to health care,1,2 as well as the fre-
quency of risk factors for and prevalence or incidence of
non-communicable diseases;3–7 importantly, these differen-
ces are observed both between and within countries in
LAC.8,9 LAC countries share a large burden of non-
communicable (e.g. diabetes and hypertension) and cardio-
vascular (e.g. ischaemic heart disease) diseases, with these
conditions standing as the leading causes of morbidity, dis-
ability and mortality in most of LAC.10–12 These epidemio-
logical estimates—e.g. morbidity—cannot inform about risk
factors or risk prediction, which are relevant to identify pre-
vention avenues. Cohort studies, on the other hand, could
provide this evidence. Pooled analysis, using data from mul-
tiple cohort studies, have additional strengths such as in-
creased statistical power and decreased statistical
uncertainty.13 LAC cohort studies have been under-repre-
sented,14 or not included at all,15–17 in international efforts
aimed at pooling data from multiple cohort studies. We
therefore set out to pool data from LAC cohorts to address
research questions that individual cohort studies would not
be able to answer.
Drawing from previous successful regional enterprises
(e.g. Asia Pacific Cohort Studies Collaboration),18,19 we
established the Cohorts Consortium of Latin America and
the Caribbean (CC-LAC). The main aim of the CC-LAC is
to start a collaborative cohort data pooling in LAC to ex-
amine the association between cardio-metabolic risk
factors (e.g. blood pressure, glucose and lipids) and non-
fatal and fatal cardiovascular outcomes (e.g. stroke or
myocardial infarction). In so doing, we aim to provide re-
gional risk estimates to inform disease burden metrics, as
well as other ambitious projects including a cardiovascular
risk score to strengthen cardiovascular prevention in LAC.
Initial funding has been provided by a fellowship from
the Wellcome Trust Centre for Global Health Research at
Imperial College London (Strategic Award, Wellcome
Trust–Imperial College Centre for Global Health
Research, 100693/Z/12/Z). Additional funding is being
provided by an International Training Fellowship from the
Wellcome Trust (214185/Z/18/Z). At the time of writing,
the daily operations and pooled database are hosted at
Imperial College London, though a mid-term goal is to
transfer this expertise and operations to LAC. The collabo-
ration relies fundamentally on a strong regional network
of health researchers and practitioners.
Who is in the cohort?
We have harmonized and pooled approximately
population-based cohort data on cardio-metabolic risk
factors and outcomes, i.e. participants were not recruited
based on disease (e.g. cohort of stroke survivors) or risk
factor (e.g. cohort of smokers) history. Data have been
collated by the CC-LAC, a LAC network of health
researchers and practitioners. The database was collated
using multiple data identification sources. First, we
accessed publicly available cohort data through each
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study’s website or data repository. Second, we conducted
a systematic search in Medline, Embase and SciELO, a
LAC-based search engine to identify cohort studies with
peer-reviewed publications in regional journals. The
search query included country terms (countries in LAC),
cohort studies (e.g. cohort stud*), and cardiovascular out-
comes (e.g. stroke); the search query is available in
Supplementary data p. 02, available as Supplementary
data at IJE online. We invited all eligible cohorts to join
the CC-LAC requesting access to anonymized individual-
level data. Third, enquiries among LAC researchers also
helped identify or approach principal investigators of the
identified cohorts. LAC members of the Non-
Communicable Disease Risk Factor Collaboration (NCD-
RisC)20 also helped identify additional data sources.
Sources that led to the identification of the collaborating
cohort studies are shown in Supplementary data pp. 03–
06, available as Supplementary data at IJE online. The
project procedures were approved by the Institutional
Review Board at Universidad Peruana Cayetano Heredia
(UPCH), Lima, Peru.
Data sources were included in the CC-LAC database if
they had at least a baseline and one follow-up round, in-
cluded LAC populations living in LAC, and participants
were not recruited exclusively based on the presence of a
risk factor or disease. No restrictions were set regarding a
minimum sample size at baseline or follow-up duration, sex
or age profiles. Anonymized individual record data were re-
ceived, harmonized and pooled by the CC-LAC. During the
harmonization process, we excluded participants who by
the time of the baseline assessment had had a cardiovascular
event (e.g. stroke or myocardial infarction). Implausible val-
ues in selected risk factors were excluded as follows:5–7,21
body mass index (BMI <10 kg/m2 or >80 kg/m2), systolic
blood pressure (<70 mmHg or >270 mmHg), diastolic
blood pressure (<30 mmHg or >150 mmHg), total choles-
terol (<1.75 mmol/L or >20.00 mmol/L), high-density lipo-
protein (HDL)-cholesterol (<0.40 mmol/L or >5.00 mmol/
L), and fasting glucose (<2.50 mmol/L or >30.00 mmol/L)
(Supplementary data are available at IJE online p. 07).
Notably, BMI was computed based on measured weight
and height in all but one Mexican cohort,22 yet the
self-reported weight and height closely correlated with mea-
sured estimates.23
At the time of writing, i.e. first datalock on 29 March
2020, 32 cohorts with data on cardiovascular outcomes
have been pooled. Seven additional cohorts have joined the
CC-LAC but are currently working to provide cardiovas-
cular outcomes, thus these 7 cohorts have not been pooled
yet. To date, the CC-LAC is therefore a consortium of 39
cohorts in 13 LAC countries (Figure 1).
Among those cohorts we currently have pooled, there
are two multi-country studies: Centro de Excelencia en
Salud Cardiovascular para América del Sur (CESCAS)
Cohort (Argentina, Chile and Uruguay)24 and the 10/66
Study (Cuba, Dominican Republic, Peru, Venezuela,
Mexico and Puerto Rico),25,26 whereas the other cohort
studies were based in only one country. The largest sample
size is with The Mexican Teachers’ Cohort (Table 2).22 A
list of all pooled cohorts along with supporting references
is presented in Supplementary data pp. 03–06, available as
Supplementary data at IJE online.
The aforementioned 7 cohorts that have not been pooled
because cardiovascular outcomes are not yet available in-
clude: CRONICAS Cohort Study (Peru),27 Mexican Health
& Aging Study (Mexico),28 Puerto Rican Elderly Health
Conditions (Puerto Rico),29 Costa Rican Longevity and
Healthy Aging Study (CRELES) 1945–1955 Retirement
Cohort (Costa Rica),30 Influence of Biopsychosocial Factors
on the Survival of the Elderly in Northeast Brazil—A
Prospective Study (Brazil),31 Baependi Heart Study
(Brazil)32 and MONICA-VITÓRIA study (Brazil).33
The pooled dataset including all cohorts is not designed
to be fully representative of the populations of regions and
countries in which they have been conducted.
Nevertheless, the results provided by this consortium will
be informative for most of the LAC region, where large,
longitudinal and multi-country studies remain insufficient
in the field of cardiovascular diseases risk prediction. This
consortium aims to advance the regional scientific evidence
by overcoming the limitations of individual cohorts, e.g.
studies with small sample size or limited number of events,
while building upon a strong collaborative network of
investigators.
How often have they been followed up?
The CC-LAC has pooled the baseline assessment and the
latest follow-up available for each cohort; for the purpose
of this consortium all subjects have been followed once,
i.e. at baseline and one follow-up. All pooled individuals
have the outcomes of interest, either non-fatal or fatal car-
diovascular events (or censored). At the time of the first
datalock, the 32 pooled cohorts had a mean follow-up
time to the first cardiovascular non-fatal/fatal event of
8.50 (median ¼ 8.80) years, ranging from <1.0 to
27.7 years.
Figure 2 shows the number of cohort studies and the
percentage of the pooled sample size at baseline. Most
pooled cohorts started in the 2000s. Furthermore, 15.7%
(n¼ 27 409) of the pooled sample had <5 years of follow-
up, 59.3% (n¼ 103 254) between 5 and 9 years and
25.0% (n¼ 43 517) >10 years of follow-up.
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What has been measured?
Table 1 shows the number of observations per pooled
cardio-metabolic risk factor. In addition to these variables,
some cohorts have collected additional anthropometric
measurements (e.g. waist/hip circumference or skinfold
thickness) and laboratory data (e.g. Glycated hemoglobin
(HbA1c), triglycerides, low-density lipoprotein (LDL)-cho-
lesterol). Table 2 depicts the cardio-metabolic risk factors
available across the pooled cohorts, and Supplementary
data pp. 17–18, available as Supplementary data at IJE on-
line, show further information on these variables at follow-
up rounds. In addition to clinical cardio-metabolic risk fac-
tors, we have pooled two relevant socio-demographic indi-
cators: place of residence (urban or rural) and schooling
(years of education).
Two outcomes of interest have been harmonized and
pooled, these are non-fatal and fatal cardiovascular events:
haemorrhagic and ischaemic stroke, myocardial infarction
(including revascularization), and mortality due to these
conditions, as well as sudden death. Where relevant, these
outcomes have been adjudicated or extracted from reliable
sources, such as clinical records or death registries. Details
on the ascertainment methods of these outcomes are pro-
vided in Supplementary data pp. 8–16, available as
Supplementary data at IJE online.
At the time of the first datalock, data from 174 180
individuals have been pooled: 171 937 (98.7%) have com-
plete follow-up or were censored (e.g. lost-to follow-up or
death by other causes), 578 (0.3%) have had a first non-
fatal cardiovascular event and 1665 (1.0%) have experi-
enced a fatal cardiovascular event (Table 1).
What has it found? Key findings and
publications
This is the first of a series of anticipated outputs and there-
fore constitutes a key initial publication to provide a gen-
eral overview of this regional long-needed endeavour. This
cohort profile aims to inform the international research
and clinical community about our ongoing efforts and
inform them of our anticipated forthcoming outcomes.
Our ongoing work includes: (i) age-specific risk estimates
of cardio-metabolic risk factors on cardiovascular non-
fatal and fatal outcomes; (ii) comparative risk assessment
of current versus ideal levels of cardio-metabolic risk fac-
tors based on regional age-specific risk estimates and sur-
vey data; and (iii) a novel risk score for cardiovascular
events based on LAC hazard estimates, and country-
specific re-calibration with LAC population-based esti-
mates of risk factors. Although other relevant efforts have
Figure 1 Number of pooled cohorts and participants by country in Latin America and the Caribbean. Based on the 32 pooled cohort units (total sample
size ¼ 174 180). A unit is a cohort-country, i.e. cohorts in multiple countries are counted as many times as countries were included (e.g., CESCAS-
Argentina, CESCAS-Chile and CESCAS-Uruguay)24.
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provided cardiovascular risk charts for LAC,34,35 they all
relied on hazard estimates from cohorts outside LAC
which may not accurately apply to LAC populations.
Besides scientific publications and other relevant out-
puts, CC-LAC has found that several cohort studies have
been conducted in LAC and provide strong data to ad-
vance the knowledge of cardiovascular health in LAC.
Probably, these cohort studies were not included in previ-
ous international cohort data pooling efforts because of
language barriers or because LAC cohorts are rather
young, i.e. started mostly in the 2000s. Moreover, CC-
LAC has demonstrated that it is feasible to conduct a
large-scale cohort data pooling effort across LAC. We en-
courage other research groups working in different fields
across health sciences (e.g. infectious diseases, climate
change and maternal/child health) to also embark on simi-
lar efforts. .
What are the main strengths and
weaknesses?
The main strength of the CC-LAC is its regional scope
and the large sample size. As discussed before (see ‘Why
was the cohort set up?’ section), LAC has not partici-
pated in other global cohort data-pooling efforts to study
cardiovascular risk factors and outcomes, leaving room
to study cardio-metabolic risk estimates in this region.
This work is therefore the first-ever cohort data-pooling
study in LAC, which will ultimately produce solid evi-
dence to guide clinical and public health practice in LAC.
Previous data-pooling efforts in LAC have only focused
on cross-sectional or survey data, and have shown
relevant differences in relation to high-income coun-
tries.36,37 CC-LAC will complement and move these
efforts to the next level, achieving larger impact in LAC
healthcare practice, research and policy. Moreover, the
fact that most of the pooled cohorts have begun in recent
years is also a strength. They will provide evidence based
on contemporary estimates, reflecting the present epide-
miological scenario. The CC-LAC has managed to har-
monize key cardio-metabolic risk factors that were
measured following consistent protocols, e.g. repeated
blood pressure measurements or standard laboratory
methods for biomarkers. Lastly, with the large sample
size, other relevant outcomes, such as diabetes risk, may
also be investigated.
Data pooling comes with methodological challenges.
Understanding the heterogeneity among cohorts in terms
of population and sampling methodology, as well as varia-
bles collection and ascertainment, is relevant to find the
best way to pool and harmonize available cohort data.
Additional sources of heterogeneity, such as different levels
of non-response rates, would be a limitation of any cohort
data-pooling project. Future results should be interpreted
considering all this and other limitations specific to each
research question.
Like other cohort pooling studies, among the weak-
nesses we should point out the heterogeneity in the defi-
nition of cardiovascular events. Although pooled cohorts
have followed adjudication processes, or these outcomes
were based on death certificates, data were sometimes
registered as 10th revision of the International Statistical
Classification of Diseases and Related Health Problems
(ICD-10) codes or in broader categories (e.g. cardiovas-
cular deaths). This prevents us from studying some spe-
cific outcomes, such as haemorrhagic versus ischaemic
stroke. This is not a criticism on our cohorts, but a call to
health and vital registries authorities as well as science
funders in LAC. Opportunities for additional follow-up
rounds of established cohort studies, or to conduct
follow-up rounds of large projects that may have been
initiated as cross-sectional surveys could be supported. In
this regard, for example, the PERU MIGRANT Study
was established as a cross-sectional project,38 though
Table 1. Number of available observations per pooled vari-
able of interest, based on 32 pooled cohorts including
174 180 individuals
Variable Sample size
Sex (male and female) 29 474 and
144 694
Body mass index (kg/m2) 152 412
Total cholesterol (mg/dL) 54 255
HDL-cholesterol (mg/dL) 39 566
Fasting glucose (mg/dL) 53 518
Systolic blood pressure (mmHg) 63 066
Current smoker 166 904
Location (urban/rural) 168 892
Education (none, <12 years, 12þ years) 115 485
Complete follow-up/censored 171 937
First non-fatal event 578
Fatal event 1665
Mean follow-up time (years) 8.50 (standard
deviation ¼ 3.27)
Figure 2 Number of pooled cohorts and sample size percentage accord-
ing to when the baseline assessment was conducted. Based on the 32
cohorts that have been pooled. Total sample size of 174 180.
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Table 2. Available cardio-metabolic risk factors across collaborating cohorts; further details about available variables at follow-






CESCAS, Centro de Excelencia en Salud Cardiovascular para América del Sur; GEFA-HT-UY, GEnotipo, Fenotipo y Ambiente de la HiperTensión Arterial en
UruguaY; NP, not pooled yet.
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with support from UPCH and intentional funders (e.g.
GloCal Health Fellowship Program from the University
of California Global Health Institute), the investigators
managed to conduct two follow-up rounds.39 In Jamaica,
the Jamaica Healthy Lifestyle Study, a repeated cross-
sectional survey on non-communicable diseases risk fac-
tors has recently received National Institutes of Health
(R01) funding to expand the cross-sectional work into a
true longitudinal cohort.40 Finally, another limitation is
the relative scarcity of data from the Caribbean. The CC-
LAC will provide relevant information pooling all avail-
able cohorts from this region. We strongly believe that
this cohort profile, and forthcoming publications, will al-
low us to identify additional sources from this region or
will stimulate interest among researchers from the
Caribbean to conduct local and multi-country cohort
studies.
The lack of novel or more sophisticated cardio-
metabolic risk factors may be a limitation as well; these
could include inflammation markers (e.g. high-sensitive C-
reactive protein) or lipid biomarkers (e.g. apolipoproteins).
Some of the pooled cohort studies have, nevertheless,
stored blood samples from their baseline rounds. We
strongly believe that CC-LAC will enhance visibility of
LAC cohort studies and promote regional collaboration. In
the future, additional risk factors may be measured in
some cohorts or new follow-up rounds may be conducted
to overcome current limitations.
Can I get hold of the data? Where can I find
out more?
Data availability will be prioritized among CC-LAC mem-
bers. New LAC cohort studies are welcomed to join the
CC-LAC. Expressions of interest in additional collabora-
tions will be received and handled by the CC-LAC steering
committee. For further details on our work, please contact
the corresponding author.
Supplementary Data
Supplementary data are available at IJE online.
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RH, Smeeth L, Miranda JJ. Cohort Profile: The PERU
MIGRANT Study-A prospective cohort study of rural dwellers,
urban dwellers and rural-to-urban migrants in Peru. Int J
Epidemiol 2017;46:1752f.
40. Ferguson TS, Francis DK, Tulloch-Reid MK, Younger NO,
McFarlane SR, Wilks RJ. An update on the burden of cardiovascular
disease risk factors in Jamaica: findings from the Jamaica Health and
Lifestyle Survey 2007-2008. West Indian Med J 2011;60:422–28.






/ije/advance-article/doi/10.1093/ije/dyaa073/5901737 by guest on 12 O
ctober 2020
